Edwards Lifesciences (EW) demonstrates a consistent focus on share buybacks, with a recent announcement of a $500M accelerated share buyback, causing Leerink Partners to lift their price target for the medical device company. Despite strong sales growth and robust growth in Transcatheter Mitral and Tricuspid Therapies (TMTT), the company's share price has fluctuated, stirring an investigation by the Portnoy law firm. Edward's acquisition of the remaining stake of Vectorious Medical Technologies and its heart implant reinforces the company's commitment to strengthening its portfolio.
Despite a brief setback due to a proposed acquisition of JenaValve being blocked by the FTC, Edwards has shown a resilient performance, reaching a 52-week high of 81.86 USD. Wall Street puts Edwards on the radar for Citadel Investment Group, indicating strong institutional interest. The company's Q2 reports beat expectations enhancing investor confidence. However, with strong competitors in the healthcare sector, Edwards seems to be struggling to break free from a 'hold' mode, as some analysts question the company's growth prospects. Detractors highlight product recalls and a potential class-action lawsuit amidst allegations of insider stock sales.
Edwards Lifesciences Corp EW News Analytics from Fri, 25 Oct 2024 07:00:00 GMT to Sat, 06 Sep 2025 14:26:30 GMT - Rating 2 - Innovation 6 - Information 7 - Rumor -1
